Navigation Links
Cystic Fibrosis Trial In Children Returns Positive Data
Date:4/3/2008

igned to hydrate the airway surface, improve lung hygiene and promote normal lung clearance. rhDNase is designed to improve mucus viscosity. Additional data from this trial will be presented by the independent investigator at a forthcoming scientific congress. A European, Pharmaxis sponsored, regulatory Phase III clinical trial, designed to lead to a marketing application for Bronchitol in adults and children with cystic fibrosis, is currently enrolling subjects.

Approximately 75,000 people in the major pharmaceutical markets are affected with cystic fibrosis and no products have been approved to improve lung hydration.
To find out more about Pharmaxis, go to http://www.pharmaxis.com.au.

1: rhDNase is marketed as Pulmozyme, which is a trade mark of Genentech

Inc.

SOURCE: Pharmaxis Ltd, Sydney, Australia

CONTACT: Alan Robertson - Chief Executive Officer

Ph: +61 2 9454 7200 or email alan.robertson@pharmaxis.com.au

Released through:

Australia: Virginia Nicholls, phone +61 417 610 824 or email virginia.nicholls@pharmaxis.com.au

United States:

Brandon Lewis, Trout Group, phone +1 646 378 2915 or email blewis@troutgroup.com

About the Trial

The following information is provided in accord with the ASX and AusBiotech Code of Best Practice for Reporting by Biotechnology, Medical Device and other Life Sciences Companies.

Name of Trial DPM - CF-203 (A phase II study with

Bronchitol)

Blinding Status Open label

Placebo Controlled No

Treatment Method

Route Inhalation

Frequency Twice per day

Dose levels 400 mg

Number of Subjects 20 evaluable

Subject Selection Crite
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients
2. Genetic manipulation might model cystic fibrosis
3. Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis
4. Data show a decline in cystic fibrosis since introduction of prenatal carrier screening
5. Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections
6. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
7. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
8. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
9. Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc.
10. Synosia Starts Phase II Efficacy Trial For Rufinamide
11. IntelliPharmaCeutics Announces Successful Completion of a Pilot Clinical Trial for its Abuse and Alcohol Resistant Sustained Release Oxycodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... -- In recognition of World Hemophilia Day, Biogen  (NASDAQ: ... more than 15 prominent landmarks red throughout the ... Zakim Bridge and Prudential Tower, Chicago,s ... and Denver,s Coors Field . ... and coincide with hemophilia community events in a dozen locations ...
(Date:4/16/2015)... , April 16, 2015 ... the Russian pharmaceutical investment and R&D group, ... collaboration for research, development and commercialization of ... with the intention to stimulate the ...      (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     (Logo: ...
(Date:4/16/2015)... Avelas Biosciences, an in vivo ... today that it has initiated a Phase 1b study ... with primary, non-recurrent breast cancer undergoing surgery. In commencing ... of Steven Chen , M.D., as vice president ... escalation study will enroll up to 39 women with ...
(Date:4/16/2015)... 2015 Fairleigh Dickinson University ( ... to become the Executive Director of the Rothman ... the kick-off of the Initiative for Patient Centered ... Gulfo, under the Rothman Institute of Innovation and ... in collaboration with FDU’s School of Pharmacy’s Center ...
Breaking Biology Technology:Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
... by a group at the University of Maryland (UMd), ... research and an age-old metallurgy technique to produce an ... class of sensors and micromechanical devices controlled by magnetism.* ... notable, among other things, for not using rare-earth elements ...
... Nov. 23, 2011  Puma Biotechnology, Inc., a development stage ... the Company completed the second tranche of its $60 ... October 5, 2011, Puma sold approximately 14.7 million shares ... purchase price of $3.75 per share, resulting in gross ...
... Modern Mobility Aids, Inc. (OTCBB: MDRM) (the "Company") ... financing required to execute its closing agreement to acquire ... ("LumiGene"). Modern Mobility Aids, Inc. is a ... and development in the Bio-Pharma sector as well as ...
Cached Biology Technology:New magnetic-field-sensitive alloy could find use in novel micromechanical devices 2Puma Biotechnology Announces Completion of Private Placement 2Puma Biotechnology Announces Completion of Private Placement 3Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies 2Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies 3
(Date:3/31/2015)... NEW YORK , March 31, 2015   ... announced the launch of the Post-Surgical Pain Management TRACKER, ... data products tracking usage trends in the medical device ... monthly access to data including treatment volumes, market share, ... manage the pain associated with joint surgery. ...
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the ... Business Report" report to their offering. This report ... Thousands by the following Segments: Face Biometrics, and Voice Biometrics. The ... , Japan , Europe ... & Africa , and Latin ...
(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... , This release is available in Spanish ... at the Institute for Research in Biomedicine (IRB Barcelona), reveal ... the one known to date. Found in the cell membrane, ... of genes that make the cell divide, grow, migrate, specialise ...
... Helicobacter pylori , a bacterium found in about 50% of ... cancer. In an article for F1000 Medicine Reports , Seiji ... pylori infections Infection by the H. pylori ... do not have symptoms, but many develop problems including stomach ulcers. ...
... of Minnesota have created a molecular image of a system ... a breakthrough for biology and could provide insights to minimize ... electricity around the country. The research, led by ... Sciences, is published in the March 12 issue of ...
Cached Biology News:Opposing functions of a key molecule in the development of organisms 2Opposing functions of a key molecule in the development of organisms 3Preventing gastric cancer with antibiotics 2U of Minnesota researcher discovers how electricity moves through cells 2
The Hybrid Hunter Yeast Two-Hybrid System uses the activation of reporter genes to indicate positive protein-protein interactions. Two reporters are used an auxotrophic marker and lacZ....
Sprague Dawley rats, 7-8 weeks of age, mixed gender; collected by exsanguination in Alsever's solution at 1:2 dilution...
... of BAC (100+kb), fosmid (40kb), and large ... than any othe BAC vector. On command ... and easy recombinant DNA purification. Available with ... VC) vectors for the highest insert stability. ...
... cloning of BAC (100+kb), fosmid (40kb), and ... stability than any othe BAC vector. On ... yields and easy recombinant DNA purification. Available ... (pSMART VC) vectors for the highest insert ...
Biology Products: